Cerus Endovascular has received CE Mark approval for its Neqstent Coil Assisted Flow Diverter device designed for the treatment of intracranial aneurysms.

Neqstent is an adjunctive intrasaccular flow diverter device intended for the treatment of a range of aneurysm morphologies, including wide-necked bifurcation and bifurcation aneurysms.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

It allows stable aneurysm neck coverage for the placement of embolisation coils within the sac and long-term occlusion of the aneurysm.

Cerus Endovascular president Dr Stephen Griffin said: “Many physicians already have firsthand experience using embolisation coils and the Neqstent will serve as an intrasaccular flow diverting device, which will work in combination with embolisation coils.

“Our goal is to offer a breadth of solutions for the treatment of these aneurysms. Physicians who have used the Neqstent comment on its ease of use through its controlled deliverability and deployment.”

The company’s new device is a further expansion of its portfolio of implant technologies, which target the neck of the aneurysm sac.

Cerus Endovascular plans to launch the device through a controlled market release across the EU. It is expected to be commercially available towards the end of this year.

Cerus Endovascular chairman Dr Sam Milstein said: “Once again, our remarkable team of dedicated professionals continue to widen and diversify our product portfolio to bring critical products to market, helping to position Cerus as a key solution provider within the industry.

“On behalf of the entire Cerus team, we would like to acknowledge the heroic and extraordinary sacrifices being made on a daily basis by healthcare workers, first-responders and the public at large, during this devastating pandemic.”